445 related articles for article (PubMed ID: 23335275)
21. Approaches to transfusion therapy and iron overload in patients with sickle cell disease: results of an international survey.
Vichinsky EP; Ohene-Frempong K;
Pediatr Hematol Oncol; 2011 Feb; 28(1):37-42. PubMed ID: 20673029
[TBL] [Abstract][Full Text] [Related]
22. Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial.
Alvarez O; Yovetich NA; Scott JP; Owen W; Miller ST; Schultz W; Lockhart A; Aygun B; Flanagan J; Bonner M; Mueller BU; Ware RE;
Am J Hematol; 2013 Nov; 88(11):932-8. PubMed ID: 23861242
[TBL] [Abstract][Full Text] [Related]
23. Sickle cell disease-related pediatric medical expenditures in the U.S.
Amendah DD; Mvundura M; Kavanagh PL; Sprinz PG; Grosse SD
Am J Prev Med; 2010 Apr; 38(4 Suppl):S550-6. PubMed ID: 20331957
[TBL] [Abstract][Full Text] [Related]
24. Trends in comorbid sickle cell disease among stroke patients.
Ovbiagele B; Adams RJ
J Neurol Sci; 2012 Feb; 313(1-2):86-91. PubMed ID: 21992814
[TBL] [Abstract][Full Text] [Related]
25. Examining the effectiveness of hydroxyurea in people with sickle cell disease.
Lanzkron S; Haywood C; Fagan PJ; Rand CS
J Health Care Poor Underserved; 2010 Feb; 21(1):277-86. PubMed ID: 20173269
[TBL] [Abstract][Full Text] [Related]
26. Recent advances in improving the management of sickle cell disease.
Inati A
Blood Rev; 2009 Dec; 23 Suppl 1():S9-13. PubMed ID: 20116638
[TBL] [Abstract][Full Text] [Related]
27. Prevalence, treatment, and outcomes of renal conditions in pediatric sickle cell disease.
Stallworth JR; Tripathi A; Jerrell JM
South Med J; 2011 Nov; 104(11):752-6. PubMed ID: 22024785
[TBL] [Abstract][Full Text] [Related]
28. Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke.
Scothorn DJ; Price C; Schwartz D; Terrill C; Buchanan GR; Shurney W; Sarniak I; Fallon R; Chu JY; Pegelow CH; Wang W; Casella JF; Resar LS; Berman B; Adamkiewicz T; Hsu LL; Ohene-Frempong K; Smith-Whitley K; Mahoney D; Scott JP; Woods GM; Watanabe M; Debaun MR
J Pediatr; 2002 Mar; 140(3):348-54. PubMed ID: 11953734
[TBL] [Abstract][Full Text] [Related]
29. Clinical complications in severe pediatric sickle cell disease and the impact of hydroxyurea.
Tripathi A; Jerrell JM; Stallworth JR
Pediatr Blood Cancer; 2011 Jan; 56(1):90-4. PubMed ID: 20922765
[TBL] [Abstract][Full Text] [Related]
30. Preventing stroke among children with sickle cell anemia: an analysis of strategies that involve transcranial Doppler testing and chronic transfusion.
Mazumdar M; Heeney MM; Sox CM; Lieu TA
Pediatrics; 2007 Oct; 120(4):e1107-16. PubMed ID: 17768181
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of adenotonsillectomy in reducing obstructive sleep apnea, cerebrovascular ischemia, vaso-occlusive pain, and ACS episodes in pediatric sickle cell disease.
Tripathi A; Jerrell JM; Stallworth JR
Ann Hematol; 2011 Feb; 90(2):145-50. PubMed ID: 20714723
[TBL] [Abstract][Full Text] [Related]
32. Long-term results using hydroxyurea/phlebotomy for reducing secondary stroke risk in children with sickle cell anemia and iron overload.
Greenway A; Ware RE; Thornburg CD
Am J Hematol; 2011 Apr; 86(4):357-61. PubMed ID: 21442640
[TBL] [Abstract][Full Text] [Related]
33. Children with sickle cell disease and human immunodeficiency virus-1 infection: use of inpatient care services in the United States.
Kourtis AP; Bansil P; Johnson C; Meikle SF; Posner SF; Jamieson DJ
Pediatr Infect Dis J; 2007 May; 26(5):406-10. PubMed ID: 17468650
[TBL] [Abstract][Full Text] [Related]
34. High resource hospitalizations among children with vaso-occlusive crises in sickle cell disease.
Raphael JL; Mei M; Mueller BU; Giordano T
Pediatr Blood Cancer; 2012 Apr; 58(4):584-90. PubMed ID: 21584938
[TBL] [Abstract][Full Text] [Related]
35. Current issues in blood transfusion for sickle cell disease.
Wahl S; Quirolo KC
Curr Opin Pediatr; 2009 Feb; 21(1):15-21. PubMed ID: 19242238
[TBL] [Abstract][Full Text] [Related]
36. Transfusion related iron overload in pediatric oncology patients treated at a tertiary care centre and treatment with chelation therapy.
Sait S; Zaghloul N; Patel A; Shah T; Iacobas I; Calderwood S
Pediatr Blood Cancer; 2014 Dec; 61(12):2319-20. PubMed ID: 25154390
[TBL] [Abstract][Full Text] [Related]
37. Characteristics and outcome of connective tissue diseases in patients with sickle-cell disease: report of 30 cases.
Michel M; Habibi A; Godeau B; Bachir D; Lahary A; Galacteros F; Fifi-Mah A; Arfi S
Semin Arthritis Rheum; 2008 Dec; 38(3):228-40. PubMed ID: 18177923
[TBL] [Abstract][Full Text] [Related]
38. Blood transfusions in children: a multi-institutional analysis of practices and complications.
Slonim AD; Joseph JG; Turenne WM; Sharangpani A; Luban NL
Transfusion; 2008 Jan; 48(1):73-80. PubMed ID: 17894792
[TBL] [Abstract][Full Text] [Related]
39. Feasibility and efficacy of chronic transfusion for stroke prevention in children with sickle cell disease.
Mirre E; Brousse V; Berteloot L; Lambot-Juhan K; Verlhac S; Boulat C; Dumont MD; Lenoir G; de Montalembert M
Eur J Haematol; 2010 Mar; 84(3):259-65. PubMed ID: 19912310
[TBL] [Abstract][Full Text] [Related]
40. Treatment patterns and economic burden of sickle-cell disease patients prescribed hydroxyurea: a retrospective claims-based study.
Shah N; Bhor M; Xie L; Halloway R; Arcona S; Paulose J; Yuce H
Health Qual Life Outcomes; 2019 Oct; 17(1):155. PubMed ID: 31619251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
